IP Library Granted Patent US 11,312,698
Granted Patent B2
US 11,312,698 · App. 16/896,135 · Granted Apr 26, 2022

Fosnetupitant chloride hydrochloride having improved stability

Inventors: Luca Fadini (Giubiasco, CH); Peter Manini (Giubiasco, CH); Claudio Pietra (Como, IT); Claudio Giuliano (Como, IT); Emanuela Lovati (Mendrisio, CH); Roberta Cannella (Varese, IT); Alessio Venturini (Varese, IT); Valentino J. Stella (Lawrence, KS)
Assignee: Helsinn Healthcare SA
C07D401/04A61K9/0019A61K31/44A61K31/473A61K31/496A61K31/56A61K31/573A61K31/675A61K45/06A61P1/08A61P13/10A61P25/22A61P25/24C07D213/74C07D213/89C07F9/650952
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,312,698
App. No.
16/896,135
Granted
Apr 26, 2022
Kind
B2
Abstract

Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:

Claims (21)

1. Fosnetupitant chloride hydrochloride having the following formula:

wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days.

2. The fosnetupitant chloride hydrochloride of claim 1 , wherein the degradants comprise netupitant.

3. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula:

wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days.

4. The pharmaceutical composition of claim 3 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant.

5. An injectable pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula:

wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days.

6. The injectable pharmaceutical composition of claim 5 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant.

7. Fosnetupitant chloride hydrochloride having the following formula:

wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and

wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days.

8. The fosnetupitant chloride hydrochloride of claim 7 , wherein the degradants comprise netupitant.

9. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula:

wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and

wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days.

10. The pharmaceutical composition of claim 9 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant.

11. An injectable pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula:

wherein the fosnetupitant chloride hydrochloride is in the form of an anhydrate; and

wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days.

12. The injectable pharmaceutical composition of claim 11 , wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
Continuity (7)
Continuation 16228835 · Dec 21, 2018
Continuation 15874325 · Jan 18, 2018
Continuation 15194984 · Jun 28, 2016
Continuation 14360991
Continuation In Part 13478361 · May 23, 2012
Provisional Application 61564537 · Nov 29, 2011
Related Publication 20200399240A1 · Dec 24, 2020